Eiger BioPharmaceuticals names new vice president of Global Hepatitis Delta Virus Clinical Development
6 June 2019 -

Eiger BioPharmaceuticals Inc (Nasdaq: EIGR), a company focused on the development and commercialisation of therapies for rare diseases, announced yesterday that it has named Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA as its new vice president of Global Hepatitis Delta Virus Clinical Development.

Dr Yogaratnam's clinical development experience covers more than a decade in large pharma and biotechnology companies with specialisation in Hepatitis B and Hepatitis C, including direct-acting antivirals, immune-based small molecules, and therapeutic vaccines and biologics. He was most recently senior medical director at Janssen Biopharma, where he led the early drug development process of an HBV capsid assembly modulator from late pre-clinical development into Phase 2a drug development. He was earlier chief medical officer at MIFCOR Inc, responsible for creating portfolio strategy and managing the company's clinical development pipeline. Earlier, he was medical director at Vertex and served as a medical lead on the anti-HCV protease inhibitor, telaprevir (INCIVEK), and served as the Vertex Clinical Lead in the Joint Strategic Alliance Team with Janssen Pharmaceutical. He started his industry career at Bristol Myers Squibb, which included a role as medical director in the development of peginterferon lambda for HCV.

David Cory, president and CEO, said, 'Jeysen's background and experience in liver disease and antiviral drug development align well with our current and future HDV program needs as we advance Lonafarnib in the first-ever Phase 3 global study for HDV and Peginterferon Lambda toward Phase 3 for HDV. Eiger's mission is to deliver multiple, first-in-class, treatment options for HDV patients, and Jeysen is ideally suited to take our program to the next level.'